A New Era of Precision Therapy: FDA Approves Atezolizumab for Adjuvant Treatment of ctDNA MRD-Positive Bladder Cancer Post-Surgery

　　On May 15,2026,the U.S.Food and Drug Administration approved atezolizumab and its subcutaneous formulation for the adjuvant treatment of adult patients with muscle-invasive bladder cancer who have undergone radical cystectomy and have been confirmed to have circulating tumor DNA molecular residual disease positivity as detected by an FDA-authorized test.This approval signifies a pivotal shift towards using liquid biopsy to precisely identify high-risk patients,representing a major milestone in precision medicine for solid tumors.

　　The therapeutic agent,developed and manufactured by Genentech,is available in both intravenous and subcutaneous formulations.The crucial companion diagnostic is the Signatera CDx test by Natera,specifically authorized to identify patients eligible for adjuvant atezolizumab treatment.

　　Muscle-invasive bladder cancer is an aggressive disease.Even after curative-intent radical surgery,many patients harbor minimal residual disease undetectable by conventional means,leading to a high risk of recurrence.ctDNA MRD testing can sensitively detect these microscopic residues via a blood draw,often months before radiographic recurrence,enabling precise stratification of patients at genuine high risk who would benefit from intensified adjuvant therapy.

　　This approval was based on the pivotal Phase III IMvigor011 trial.In this study,adjuvant atezolizumab significantly delayed disease recurrence and improved overall survival in post-surgical patients with ctDNA MRD positivity.The treatment reduced the risk of disease recurrence or death by 36%compared to placebo,with a clinically meaningful improvement in median overall survival.

　　Regarding safety,the atezolizumab prescribing information carries important warnings for immune-mediated adverse reactions,infusion-related reactions,and others.It is contraindicated during pregnancy,and patients require close monitoring during treatment.

　　The approved dosing regimens are:intravenous infusion at various intervals(every 2,3,or 4 weeks)or a novel subcutaneous injection once every 3 weeks,offering a convenient treatment option.The total treatment duration should not exceed 12 months.The treatment pathway mandates that post-surgery patients must be tested with Signatera;only those with a positive MRD result initiate atezolizumab.Patients with an initial negative result require periodic blood surveillance for up to one year,with treatment initiation recommended upon conversion to a positive status.

　　This approval fundamentally transforms the traditional"one-size-fits-all"approach to adjuvant therapy in bladder cancer.By leveraging molecular evidence of residual disease,it ensures high-risk patients receive timely,effective intervention while sparing low-risk patients unnecessary treatment toxicity.This model establishes a new paradigm for post-operative management across other solid tumors.